Oncology
Adenoviral p53 gene transfer and chemotherapy fight ovarian cancer cell growth
Published in Gene Therapy Weekly, October 7th, 2004
According to a study from Germany, "clinical adenoviral p53 gene therapy has been shown by us and others to inhibit tumor growth of ovarian cancer with endogenous mutant p53. This study was designed to test the cooperative antitumor effect of standard combination chemotherapy using paclitaxel and carboplatin together with adenoviral p53 gene transfer in the presence of wild-type and mutant p53. Seven ovarian cancer cell lines with mutant p53 and seven ovarian cancer cell lines with wild-type p53 were tested."
"An E1-deleted adenovirus type 5 expressing p53 (ACNp53) was...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-10-07)
More Articles from Gene Therapy Weekly
- Breast Cancer
RNA inhibition counteracts the growth of human mammary tumor xenografts - Chemotherapy
Overexpressed dominant-negative FANCA helps cisplatin battle tumors - Gene Promoters
Tumor-specific gene therapy targets uterine cervical cancer - Gynecology
Suicide gene therapy makes ovarian cancer susceptible to chemotherapy - Adverse Drug Effects
Calbindin-D-28K protects renal tubular cells from cyclosporine toxicity - Angiology
Rac1 GTPase is a strategic target for tumor elimination - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
